Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Immunotech BiopharmHKSE:06978 +1.30%17 EBIT per Share is HK$-0.45 as of Dec. 2025. GuruFocus rates HKSE:06978 with a GF Score™ of 17/100. The stock has 4 warning signs investors should review. Among 1,171 Biotechnology companies, Immunotech Biopharm ranks better than 51.24% on this metric.
Immunotech Biopharm's EBIT per Share for the
six
months ended in Dec. 2025 was HK$-0.20.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was HK$-0.45.
During the past 3 years, the average EBIT per Share Growth Rate was 16.30% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 20.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Immunotech Biopharm's EBIT per Share or its related term are showing as below:
HKSE:06978'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -102 Med: 16.3 Max: 22.9
Current: 16.3
During the past 8 years, the highest 3-Year average EBIT per Share Growth Rate of Immunotech Biopharm was 22.90% per year. The lowest was -102.00% per year. And the median was 16.30% per year.
HKSE:06978's 3-Year EBIT Growth Rate is ranked better than 51.24% of 1171
companies
in the Biotechnology industry
Industry Median: 15.3
vs HKSE:06978: 16.30
Immunotech Biopharm (HKSE:06978) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Immunotech Biopharm EBIT per Share Related Terms
Immunotech Biopharm EBIT per Share Historical Data
* Premium members only.
The historical data trend for Immunotech Biopharm's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-0.45
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Immunotech Biopharm (HKSE:06978) has a EBIT per Share of HK$-0.45 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Immunotech Biopharm and its competitors. According to the industry distribution chart, Immunotech Biopharm ranks #571 out of 1171 companies in the Biotechnology industry, placing it in the top 48.8%.
Is Immunotech Biopharm's EBIT per Share too high?
Immunotech Biopharm's current EBIT per Share is HK$-0.45. Based on the distribution chart, Immunotech Biopharm ranks #571 out of 1171 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Immunotech Biopharm has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Immunotech Biopharm's EBIT per Share compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Immunotech Biopharm ranks #571 out of 1171 companies for EBIT per Share. This puts Immunotech Biopharm in the upper half of its industry. The industry median EBIT per Share is 15.30. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.30, based on 1,171 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Immunotech Biopharm and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Immunotech Biopharm's current EBIT per Share is HK$-0.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Immunotech Biopharm stock overvalued right now?
Immunotech Biopharm (HKSE:06978) has a current EBIT per Share of HK$-0.45. The current EBIT per Share is HK$-0.45. Immunotech Biopharm's overall GF Score™ is 17/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Immunotech Biopharm (HKSE:06978), the current EBIT per Share is HK$-0.45 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Immunotech Biopharm Ltd is a cellular immunotherapy biopharmaceutical company in China. The company is focused on the research, development, and commercialization of T-cell immunotherapy. Its product EAL is a multi-target cellular immunotherapy product for the treatment of various types of cancer. Its product pipeline features classes of cellular immunotherapy products, including both non-genetically modified and genetically modified products, as well as both multi-target and single-target products. Its other products include the CAR-T cell series and the TCR-T cell series.
17GF Score
Get the complete analysis for HKSE:06978
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:06978 has been successfully added to your 
